197 results on '"Lehmann, Fredrik"'
Search Results
2. Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
3. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
4. Prognostic significance of esterase gene expression in multiple myeloma
5. PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
6. Melflufen: A Journey from Discovery to Multi-Kilogram Production
7. Application of triple quadrupole mass spectrometry for the characterization of antibody–drug conjugates
8. Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses
9. A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action
10. Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention
11. Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia
12. The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies
13. Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma
14. A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma
15. Potential Use of Supercharging Agents for Improved Mass Spectrometric Analysis of Monoclonal Antibodies and Antibody–Drug Conjugates
16. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
17. The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
18. Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma
19. Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity
20. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
21. Optimization of isochromanone based urotensin II receptor agonists
22. Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
23. Novel and potent small-molecule urotensin II receptor agonists
24. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
25. Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
26. Evolution of Nitrogen-Based Alkylating Anticancer Agents
27. The Wittig bioconjugation of maleimide derived, water soluble phosphonium ylides to aldehyde-tagged proteins
28. Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells
29. Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma
30. Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model
31. Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing
32. Efficient large scale microwave assisted Mannich reactions using substituted acetophenones
33. Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody–Drug Conjugates
34. Azithromycin prevents airway epithelial barrier dysfunction induced by sulphur dioxide inhalation
35. Azithromycin maintains barrier integrity in a cell model of ventilator induced lung injury
36. Abstract 1843: Melflufen efficacy in multiple myeloma with TP53 aberrations
37. Abstract 5205: Melflufen, a peptide-conjugated alkylator, shows efficacy in breast cancer cell lines
38. Abstract 190: Prognostic significance of esterase gene expression in multiple myeloma
39. Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
40. Magnetic Beads for Desalting of Monoclonal Antibodies and Antibody–Drug Conjugates
41. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
42. In Vitro and inVivo Activity of Melflufen in Amyloidosis
43. Aminopeptidase gene expression in myeloma
44. Isochromanone-based urotensin-II receptor agonists
45. Development of a Safe Process for Manufacturing of the Potent Anticancer Agent Melflufen Hydrochloride
46. Azithromycin Has Lung Barrier Protective Effects in a Cell Model Mimicking Ventilator-Induced Lung Injury.
47. Development of a Synthesis of Kinase Inhibitor AKN028
48. Qualitative analysis of antibody–drug conjugates (ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCs
49. Effect of mobile phase composition on the analysis of aggregates of antibody drug conjugates (ADCs) using size exclusion chromatography
50. In Vitro and in Vivo Activity of Melflufen in Amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.